The Gross Law Firm Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1]. Summary by Sections Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA, including: - Lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls [1]. - Unlikelihood of FDA approval for the MOLBREEVI BLA in its current form [1]. - Delay in submission of the MOLBREEVI BLA within the previously represented timeframe [1]. - Increased likelihood of needing to raise additional capital due to regulatory approval delays [1]. - Overall, the public statements made by the defendants were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased shares of Savara Inc. during the specified class period are encouraged to register for the class action by November 7, 2025, to potentially be appointed as lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].